$30M Up Front to S*Bio
Cell Therapeutics Lands Sweet Deal for JAK Drug
By Jennifer Boggs
Friday, April 20, 2012
Seattle-based Cell Therapeutics Inc. nabbed worldwide rights to Phase III-ready JAK2 inhibitor pacritinib from S*Bio Pte Ltd., of Singapore, for a relatively modest up-front payment of $30 million half of that in convertible preferred stock and up to $132.5 million in regulatory and sales milestones if the drug lives up to its full potential.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.